Literature DB >> 27534555

Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.

Elisa Ten Hacken1, Mariela Sivina1, Ekaterina Kim1, Susan O'Brien1, William G Wierda1, Alessandra Ferrajoli1, Zeev Estrov1, Michael J Keating1, Thomas Oellerich2, Cristina Scielzo3, Paolo Ghia3, Federico Caligaris-Cappio3, Jan A Burger4.   

Abstract

BCR signaling is a central pathogenetic pathway in chronic lymphocytic leukemia (CLL). Most CLL cells express BCRs of IgM and IgD isotypes, but the contribution of these isotypes to functional responses remains incompletely defined. We therefore investigated differences between IgM and IgD signaling in freshly isolated peripheral blood CLL cells and in CLL cells cultured with nurselike cells, a model that mimics the lymph node microenvironment. IgM signaling induced prolonged activation of ERK kinases and promoted CLL cell survival, CCL3 and CCL4 chemokine secretion, and downregulation of BCL6, the transcriptional repressor of CCL3 In contrast, IgD signaling induced activation of the cytoskeletal protein HS1, along with F-actin polymerization, which resulted in rapid receptor internalization and failure to support downstream responses, including CLL cell survival and chemokine secretion. IgM and IgD receptor downmodulation, HS1 and ERK activation, chemokine secretion, and BCL6 downregulation were also observed when CLL cells were cocultured with nurselike cells. The Bruton's tyrosine kinase inhibitor ibrutinib effectively inhibited both IgM and IgD isotype signaling. In conclusion, through a variety of functional readouts, we demonstrate very distinct outcomes of IgM and IgD isotype activation in CLL cells, providing novel insight into the regulation of BCR signaling in CLL.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27534555      PMCID: PMC5010921          DOI: 10.4049/jimmunol.1600915

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  57 in total

1.  Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.

Authors:  Jan A Burger; Michael J Keating; William G Wierda; Elena Hartmann; Julia Hoellenriegel; Nathalie Y Rosin; Iris de Weerdt; Ghayathri Jeyakumar; Alessandra Ferrajoli; Marylou Cardenas-Turanzas; Susan Lerner; Jeffrey L Jorgensen; Graciela M Nogueras-González; Gracy Zacharian; Xuelin Huang; Hagop Kantarjian; Naveen Garg; Andreas Rosenwald; Susan O'Brien
Journal:  Lancet Oncol       Date:  2014-08-20       Impact factor: 41.316

2.  Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status.

Authors:  C Ian Mockridge; Kathleen N Potter; Isla Wheatley; Louise A Neville; Graham Packham; Freda K Stevenson
Journal:  Blood       Date:  2007-01-25       Impact factor: 22.113

Review 3.  The pivotal position of the actin cytoskeleton in the initiation and regulation of B cell receptor activation.

Authors:  Wenxia Song; Chaohong Liu; Arpita Upadhyaya
Journal:  Biochim Biophys Acta       Date:  2013-07-23

4.  Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.

Authors:  Aleksandar Petlickovski; Luca Laurenti; Xiaoping Li; Sara Marietti; Patrizia Chiusolo; Simona Sica; Giuseppe Leone; Dimitar G Efremov
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

Review 5.  Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.

Authors:  Elisa Ten Hacken; Jan A Burger
Journal:  Biochim Biophys Acta       Date:  2015-07-17

6.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Authors:  Yair Herishanu; Patricia Pérez-Galán; Delong Liu; Angélique Biancotto; Stefania Pittaluga; Berengere Vire; Federica Gibellini; Ndegwa Njuguna; Elinor Lee; Lawrence Stennett; Nalini Raghavachari; Poching Liu; J Philip McCoy; Mark Raffeld; Maryalice Stetler-Stevenson; Constance Yuan; Richard Sherry; Diane C Arthur; Irina Maric; Therese White; Gerald E Marti; Peter Munson; Wyndham H Wilson; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

7.  B-cell receptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of chronic lymphocytic leukemia.

Authors:  David J Allsup; Aura S Kamiguti; Ke Lin; Paul D Sherrington; Zoltan Matrai; Joseph R Slupsky; John C Cawley; Mirko Zuzel
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

8.  CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.

Authors:  Antonella Zucchetto; Dania Benedetti; Claudio Tripodo; Riccardo Bomben; Michele Dal Bo; Daniela Marconi; Fleur Bossi; Debora Lorenzon; Massimo Degan; Francesca Maria Rossi; Davide Rossi; Pietro Bulian; Vito Franco; Giovanni Del Poeta; Silvia Deaglio; Gianluca Gaidano; Francesco Tedesco; Fabio Malavasi; Valter Gattei
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

9.  Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy.

Authors:  Giorgia Simonetti; Maria Teresa Sabrina Bertilaccio; Paolo Ghia; Ulf Klein
Journal:  Blood       Date:  2014-07-08       Impact factor: 22.113

10.  B cell antigen receptor signaling and internalization are mutually exclusive events.

Authors:  Ping Hou; Elizabeth Araujo; Tong Zhao; Miao Zhang; Don Massenburg; Margaret Veselits; Colleen Doyle; Aaron R Dinner; Marcus R Clark
Journal:  PLoS Biol       Date:  2006-07       Impact factor: 8.029

View more
  14 in total

1.  Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia.

Authors:  Elisa ten Hacken; Maria Gounari; Jaap Willem Back; Ekaterina Shimanovskaya; Lydia Scarfò; Ekaterina Kim; Jared Burks; Maurilio Ponzoni; Giuseppe Alvise Ramirez; William G Wierda; Zeev Estrov; Michael J Keating; Alessandra Ferrajoli; Kostas Stamatopoulos; Paolo Ghia; Jan A Burger
Journal:  Haematologica       Date:  2017-07-27       Impact factor: 9.941

2.  Targeting BTK through microRNA in chronic lymphocytic leukemia.

Authors:  Arianna Bottoni; Lara Rizzotto; Tzung-Huei Lai; Chaomei Liu; Lisa L Smith; Rose Mantel; Sean Reiff; Dalia El-Gamal; Karilyn Larkin; Amy J Johnson; Rosa Lapalombella; Amy Lehman; William Plunkett; John C Byrd; James S Blachly; Jennifer A Woyach; Deepa Sampath
Journal:  Blood       Date:  2016-10-17       Impact factor: 22.113

3.  Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.

Authors:  Elisa Ten Hacken; Rebecca Valentin; Fara Faye D Regis; Jing Sun; Shanye Yin; Lillian Werner; Jing Deng; Michaela Gruber; Jessica Wong; Mei Zheng; Amy L Gill; Michael Seiler; Peter Smith; Michael Thomas; Silvia Buonamici; Emanuela M Ghia; Ekaterina Kim; Laura Z Rassenti; Jan A Burger; Thomas J Kipps; Matthew L Meyerson; Pavan Bachireddy; Lili Wang; Robin Reed; Donna Neuberg; Ruben D Carrasco; Angela N Brooks; Anthony Letai; Matthew S Davids; Catherine J Wu
Journal:  JCI Insight       Date:  2018-10-04

Review 4.  Targeting B cell receptor signalling in cancer: preclinical and clinical advances.

Authors:  Jan A Burger; Adrian Wiestner
Journal:  Nat Rev Cancer       Date:  2018-01-19       Impact factor: 60.716

Review 5.  The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.

Authors:  Elisa Ten Hacken; Maria Gounari; Paolo Ghia; Jan A Burger
Journal:  Leukemia       Date:  2018-12-16       Impact factor: 11.528

6.  Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.

Authors:  Erika Tissino; Dania Benedetti; Sarah E M Herman; Elisa Ten Hacken; Inhye E Ahn; Kari G Chaffee; Francesca Maria Rossi; Michele Dal Bo; Pietro Bulian; Riccardo Bomben; Elisabeth Bayer; Andrea Härzschel; Julia Christine Gutjahr; Massimiliano Postorino; Enrico Santinelli; Ayed Ayed; Francesco Zaja; Annalisa Chiarenza; Gabriele Pozzato; Alexandre Chigaev; Larry A Sklar; Jan A Burger; Alessandra Ferrajoli; Tait D Shanafelt; Adrian Wiestner; Giovanni Del Poeta; Tanja Nicole Hartmann; Valter Gattei; Antonella Zucchetto
Journal:  J Exp Med       Date:  2018-01-04       Impact factor: 14.307

7.  Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.

Authors:  M K Hasan; J Yu; L Chen; Bing Cui; G F Widhopf Ii; L Rassenti; Z Shen; S P Briggs; T J Kipps
Journal:  Leukemia       Date:  2017-05-03       Impact factor: 11.528

8.  DAPK3 participates in the mRNA processing of immediate early genes in chronic lymphocytic leukaemia.

Authors:  Fraser Thomas; Katie B Holmes; Sarah Kreuz; Peter Hillmen; Pascal F Lefevre
Journal:  Mol Oncol       Date:  2020-05-03       Impact factor: 6.603

9.  The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling.

Authors:  Inna Gordiienko; Larysa Shlapatska; Valeriia Kholodniuk; Lilia Sklyarenko; Daniel F Gluzman; Edward A Clark; Svetlana P Sidorenko
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

10.  Dasatinib exacerbates splenomegaly of mice inoculated with Epstein-Barr virus-infected lymphoblastoid cell lines.

Authors:  Ryutaro Kotaki; Masaharu Kawashima; Yuichiro Yamamoto; Hiroshi Higuchi; Etsuko Nagashima; Natsumi Kurosaki; Masako Takamatsu; Yara Yukie Kikuti; Ken-Ichi Imadome; Naoya Nakamura; Ai Kotani
Journal:  Sci Rep       Date:  2020-03-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.